Topical formulations containing chitosan could be explored for localized conditions like atopic dermatitis or rosacea, leveraging its anti‐inflammatory and potentially barrier‐enhancing properties alongside MRGPRX2 inhibition. The gene discussed is MRGPRX2; the disease is rosacea.